Table 1.

Number of patients in the BLAZE-1 study that provided serum samples at each timepoint.

Treatment	Baseline	Day 3	Day 15	Day 29	Day 60	Day 85
Placebo	152	140	124	126	125	120
Bamlanivimab 700 mg	99	93	90	86	82	84
Bamlanivimab 2800 mg	104	100	90	91	91	92
Bamlanivimab 7000 mg	97	91	89	86	77	80
Bamlanivimab (2800 mg) and etesevimab (2800 mg) together	108	98	95	96	91	80

Patients received placebo, bamlanivimab alone (700, 2800, or 7000 mg), or bamlanivimab (2800 mg) and etesevimab (2800 mg) together.